Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dimethindene maleate is a **first-generation selective histamine H1 antagonist** and **anticholinergic** used for the symptomatic treatment of allergic reactions (such as urticaria, hay fever, perennial rhinitis, food and drug allergies), pruritus of various origins (insect bites, eczema, chickenpox, other pruriginous dermatoses), and as an adjuvant in allergic skin conditions[1][2][3]. It may also be used to treat anaphylactic shock and respiratory allergies. The drug acts primarily by blocking the **histamine H1 receptor** in a competitive and selective manner, offering relief of allergy symptoms[1][3][6]. The compound is also an antagonist of the **muscarinic acetylcholine receptor M2**, with minor affinity for other muscarinic subtypes[1][6]. The maleate salt form is commonly used in pharmaceutical products for improved stability and solubility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dimethindene maleate.